Q1 2025 Cytosorbents Corp Earnings Call Transcript
Key Points
- CytoSorbents Corp (CTSO) reported a solid gross margin performance of 71%, consistent with the 2024 average, indicating effective pricing and cost controls.
- The company is making progress towards reaching near breakeven by the second half of 2025, with sufficient cash to fund initiatives.
- CytoSorb, the flagship product, is used in over 270,000 devices across more than 70 countries, demonstrating its global reach and acceptance.
- The company is actively preparing for the potential commercial launch of DrugSorb ATR in the U.S. and Canada, which could open a significant market opportunity.
- CytoSorbents Corp (CTSO) has strengthened its balance sheet with a successful shareholder rights offering, increasing available liquidity by $11.8 million.
- Product sales in the first quarter of 2025 were $8.7 million, representing a 3% year-over-year decline.
- The company faced temporary disruptions in its German direct sales segment due to strategic reorganization, impacting overall sales.
- The FDA issued a denial letter for DrugSorb ATR, citing remaining open issues, which could delay its market entry.
- Health Canada's review of the DrugSorb ATR application is experiencing delays, extending beyond target timelines.
- The company reported a net loss for the quarter of $1.5 million, although this was an improvement from the previous year.
Good afternoon, ladies and gentlemen, and welcome to the CytoSorbents' first-quarter 2025 earnings conference call. (Operator Instructions)
This call is being recorded on Thursday, May 8, 2025. I would now like to turn the conference over to Mr. Adanna Alexander. Please go ahead.
Thank you, Constantine, and good afternoon, everyone. Welcome to CytoSorbents' First Quarter 2025 Financial Results and recent Business Highlights Conference Call. Joining me today from the company for prepared remarks are Dr. Phillip Chan, Chief Executive Officer; Dr. Makis Deliargyris, Chief Medical Officer; and Pete Mariani, Chief Financial Officer.
Before I turn the call over to Dr. Chan, I'd like to remind listeners that during the call, management's prepared remarks may contain forward-looking statements, which are subject to risks and uncertainties. Management may make additional forward-looking statements in response to your questions today. Therefore, the company claims protection under the safe harbor
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
